Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 21, 2018
- Accepted in final form July 30, 2018
- First Published September 26, 2018.
Article Versions
- Previous version (September 26, 2018 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Gabriel M. Moreno, MD,
- Rhea Gandhi,
- Stephanie L. Lessig, MD,
- Brenton Wright, MD,
- Irene Litvan, MD and
- Fatta B. Nahab, MD
- Gabriel M. Moreno, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rhea Gandhi,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stephanie L. Lessig, MD,
Neurocrine
NONE
Medtronic
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi Stock/Stock Options, Medical Equipment & Materials: Dexcom
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brenton Wright, MD,
NONE
NONE
NONE
PLOS One, Ad Hoc Reviewer, 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Irene Litvan, MD and
Advisory Boards: Biotie/Parkinson Study Group, Abbvie
NONE
NONE
Chief Editor: Frontiers in Movement Disorders
NONE
NONE
NONE
Toyama Pharmaceuticals
NONE
NONE
NONE
NONE
National Institutes of Health grants: 5P50 AG005131-31, 5T35HL007491, and 1U54NS092089-01
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fatta B. Nahab, MD
(1) Cala Health, (2) Global Kinetics Corporation, (3) Merz, (4) Acorda Therapeutics.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Teva
NONE
NONE
(1) Global Kinetics Corporation, (2) Biotie, (3) Tilray.
NONE
NONE
(1) International Essential Tremor Foundation
NONE
NONE
NONE
NONE
NONE
(1) Expert witness for defendant.
- Correspondence
Dr. Nahab fnahab{at}ucsd.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.